Androgen deprivation therapy for prostate cancer – an often forgotten risk factor for osteoporosis
Prostate cancer is the most common male solid organ malignancy. Almost half of the men with prostate cancer will be treated with androgen deprivation therapy (ADT) to suppress testosterone levels. While this improves disease-free survival and mortality, ADT is associated with a loss of BMD and an increased risk of fragility fracture. This complication will …